Skip to main content

Advertisement

SpringerLink
Log in

Usefulness of CTC and DTC-BM Detection for Adjuvant Therapy Effects and Prognosis Prediction in Early Breast Carcinoma: Results of 8–11 Years of Follow-up Evaluation

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Circulating tumor cells (CTCs) reportedly have been detected in the peripheral blood of more than 50% of breast carcinoma cases with distant metastases. Moreover, the survival period is shorter for patients who had more than five CTCs after a single chemotherapy treatment. However, a few data show the relationships between CTCs and expressions of disseminated tumor cells in the bone marrow (DTCs-BM), including treatment effects and prognoses in early breast carcinomas.

Methods

In this study, CTCs and DTC-BMs were measured by the CellSearch System for 20 patients with stages 1–3 carcinomas, who were followed for 8–11 years.

Results

CTCs in 2 (10%) of 20 breast carcinomas, more than 1 CTC was detected before adjuvant therapy, and both cases showed a decrease to 0 after chemotherapy. DTC-BMs in 19 (95%) of the 20 primary cases, more than 1 cell was found in the BM. After adjuvant therapy, 16 cases showed a decrease to 0–10 cells, 2 cases to 11–20 cells, and 2 cases to more than 21 cells. Six patients experienced recurrence. One of the two CTC-positive cases (>21 cells) had bone and liver metastasis within 11 months. Among the DTC-BM cases, only 1 (16.7%) of the 6 primary patients with 11–20 cells had recurrence, whereas 4 (80%) of the 5 patients with more than 21 cells had recurrence 3–6 years later.

Conclusions

Detection of DTC-BMs is useful for observing adjuvant therapy effects and for predicting relatively late-phase metastasis. The cluster status of CTCs suggests early relapsing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Tsukuma H, Ajiki W, Ioka A, Oshima A. Survival of cancer patients diagnosed between 1993 and 1996: a collaborative study of population-based cancer registries in Japan. Research Group of Population-Based Cancer Registries of Japan. Jpn J Clin Oncol. 2006;36:602–7.

    Article  PubMed  Google Scholar 

  2. Woodward WA, Vinh-Hung V, Ueno NT, Cheng YC, Royce M, Tai P. Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol. 2003;24:2910–16.

    Article  Google Scholar 

  3. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;25(353):793–802.

    Article  Google Scholar 

  4. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.

    Article  CAS  PubMed  Google Scholar 

  5. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12:4218–24.

    Article  CAS  PubMed  Google Scholar 

  6. Daskalaki A, Agelaki S, Perraki M, Apostolaki S, Xenidis N, Stathopoulos E, et al. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br J Cancer 2009;101:589–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 2008;14:2519–26.

    Article  CAS  PubMed  Google Scholar 

  8. Bidard FC, Vincent-Salomon A, Sigal-Zafrani B, Dieras V, Mathiot C, Mignot L, et al. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol. 2008;19:496–500.

    Article  PubMed  Google Scholar 

  9. Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, et al. Detection of minimal residual disease in blood and bone marrow in early-stage breast cancer. Cancer 2010;116:3330–7.

    Article  PubMed  Google Scholar 

  10. Schindlbeck C, Kampik T, Janni W, Rack B, Jeschke U, Krajewski S, et al. Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas. Breast Cancer Res. 2005;7:R1174–85.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96–102.

    Article  Google Scholar 

  12. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224–37.

    Article  PubMed  Google Scholar 

  13. Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res. 2005;11:3678–85.

    Article  PubMed  Google Scholar 

  14. Zabaglo L, Ormerod MG, Parton M, Ring A, Smith IE, Dowsett M. Cell filtration-laser scanning cytometry for the characterisation of circulating breast cancer cells. Cytometry A 2003;55:102–8.

    Article  PubMed  Google Scholar 

  15. Nora Dickson M, Tsinberg P, Tang Z, Bischoff FZ, Wilson T, Leonard EF. Efficient capture of circulating tumor cells with a novel immunocytochemical microfluidic device. Biomicrofluidics 2011;5(3):34119–915.

    Article  PubMed  Google Scholar 

  16. Schindlbeck C, Pfab G, Jueckstock J, Andergassen U, Sommer H, Janni W, et al. Prognostic relevance of disseminated tumor cells in the bone marrow of patients with primary breast cancer: results of a standardized follow-up. Anticancer Res. 2011;31:2749–55.

    CAS  PubMed  Google Scholar 

  17. Weihrauch MR, Skibowski E, Draube A, Geller A, Tesch H, Diehl V, et al. Immunomagnetic enrichment and detection of isolated tumor cells in bone marrow of patients with epithelial malignancies. Clin Exp Metastasis 2002,19:617–21.

    Article  CAS  PubMed  Google Scholar 

  18. Banys M, Müller V, Melcher C, Aktas B, Kasimir-Bauer S, Hagenbeck C, et al. Circulating tumor cells in breast cancer. Clin Chim Acta 2013;23(423):39–45.

    Article  Google Scholar 

  19. Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Juckstock J, et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse: a European pooled analysis. Clin Cancer Res. 2011;17:2967–76.

    Article  PubMed  Google Scholar 

  20. Janni W, Gastroph S, Hepp F, Kentenich C, Rjosk D, Schindlbeck C, et al. Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma. Cancer 2000;88:2252–9.

    Article  CAS  PubMed  Google Scholar 

  21. Pachmann K, Camara O, Kavallaris A, Krauspe S, Malarski N, Gajda M, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol. 2008;26:1208–15.

    Article  PubMed  Google Scholar 

  22. Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, Scharpe S, et al. Prognostic significance of disseminated tumor cells as detected by quantitative real-time reverse-transcriptase polymerase chain reaction in patients with breast cancer. Clin Breast Cancer 2006;7:146–52.

    Article  CAS  PubMed  Google Scholar 

  23. Molloy TJ, Bosma AJ, Baumbusch LO, Synnestvedt M, Borgen E, Russnes HG, et al. The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Res. 2011;13(3):R61.1–11.

  24. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 2014;28(158):1110–22.

    Article  Google Scholar 

  25. Kai K, Arima Y, Kamiya T, Saya H. Breast cancer stem cells (review). Breast Cancer 2010;17:80–5. doi:10.1007/s12282-009-0176-y (Epub 6 October 2009).

    Article  PubMed  Google Scholar 

  26. Peeters DJ, Van den Eynden GG, van Dam PJ, Prove A, Benoy IH, van Dam PA, et al. Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer. Br J Cancer 2011;104:1472–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Schindlbeck C, Andergassen U, Hofmann S, Jückstock J, Jeschke U, Sommer H, et al. Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients. J Cancer Res Clin Oncol. 2013;139:1055–62. doi:10.1007/s00432-013-1418-0 (Epub 23 March 2013).

    Article  PubMed  Google Scholar 

Download references

Disclosures

There are no commercial interest.

Author information

Authors and Affiliations

  1. Department of Breast and Endocrine Surgery, Jikei University School of Medicine, Tokyo, Japan

    Hiroshi Takeyama MD, S. Kinoshita MD & K. Uchida MD

  2. Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan

    T. Shimada MD

Authors
  1. Hiroshi Takeyama MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Shimada MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Kinoshita MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Uchida MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Takeyama MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takeyama, H., Shimada, T., Kinoshita, S. et al. Usefulness of CTC and DTC-BM Detection for Adjuvant Therapy Effects and Prognosis Prediction in Early Breast Carcinoma: Results of 8–11 Years of Follow-up Evaluation. Ann Surg Oncol 24, 1227–1233 (2017). https://doi.org/10.1245/s10434-016-5714-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-016-5714-1

Keywords

Search

Navigation